Document Information

PMID 12060810  (  )
Title Minocycline delays disease onset and mortality in a transgenic model of ALS.
Abstract Microglial activation is thought to contribute to the progression of selective motor neuron death during amyotrophic lateral sclerosis (ALS). As minocycline has been shown to inhibit microglial activation, the therapeutic efficacy of this tetracycline derivative in the G93A mice model for familial ALS was tested. This drug with proven safety delayed disease onset and dose-dependently extended the survival of the G93A mice. At 120 days of age, minocycline protected mice from loss of motor neurons and from vacuolization. These results demonstrate that interference with immuno-inflammatory responses has a beneficial effect in the ALS mice model, suggesting this to be a potential new strategy to treat ALS. Leuven, Belgium.

NOTE: Color highlight is limited to the abstract and SciMiner text-mining mode. If you see much more identified targets below from "Targets by SciMiner Summary" and "Targets by SciMiner Full list", they may have been identified from the full text.


Targets by SciMiner Summary

HUGO ID Symbol Target Name #Occur ActualStr
7873NOS2Anitric oxide synthase 2A (inducible, hepatocytes)5iNOS |
11179SOD1superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult))4superoxide dismutase 1 | SOD1 |
1499CASP1caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase)3caspase 1 |
6871MAPK1mitogen-activated protein kinase 13MAPK | p38 |
6193JAK3Janus kinase 3 (a protein tyrosine kinase, leukocyte)1janus kinase 3 |
1504CASP3caspase 3, apoptosis-related cysteine peptidase1caspase 3 |
6876MAPK14mitogen-activated protein kinase 141p38 mitogen activated protein kinase |

 

Targets by SciMiner Full list

HUGO ID Symbol Name ActualStr Score FlankingText
7873NOS2Anitric oxide synthase 2A (inducible, hepatocytes)iNOS1.9inhibits microglial activation caspase-1 and inducible nitric oxide synthetase (iNOS) iNOS up-regulation and decreases infarct size after experimental ischemia in rats
7873NOS2Anitric oxide synthase 2A (inducible, hepatocytes)iNOS1.9Second minocycline inhibits caspase-1 and caspase-3 expression decreases iNOS activity and delays mortality in a transgenic mouse model of
7873NOS2Anitric oxide synthase 2A (inducible, hepatocytes)iNOS1.9Excitotoxicity microglial activation iNOS and caspase up-regulation have all been suggested to play a
11179SOD1superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult))SOD12.2all cases and mutations of the superoxide dismutase 1 ( SOD1 gene have been identified in about 20_amp_#37 of the familial
11179SOD1superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult))SOD12.2Transgenic mice over-expressing the human SOD1 gene with a mutation identified in ALS patients develop an
11179SOD1superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult))SOD12.2Transgenic mice with the G93A human SOD1 mutation TgN(SOD1-G93A)G1H, TgN SOD1-G93A G1H were obtained from The Jackson
7873NOS2Anitric oxide synthase 2A (inducible, hepatocytes)iNOS1.9microglia as well as the concomitant induction of caspase-1 and iNOS
7873NOS2Anitric oxide synthase 2A (inducible, hepatocytes)iNOS1.9related to an inhibition of caspases and a decrease in iNOS activity _amp_#91 5 _amp_#93
6871MAPK1mitogen-activated protein kinase 1p381.7and proliferation of microglia induced by excitotoxicity by inhibiting the p38 mitogen-activated protein kinase (p38 p38 MAPK _amp_#91 6 _amp_#93
6871MAPK1mitogen-activated protein kinase 1p381.7by excitotoxicity by inhibiting the p38 mitogen-activated protein kinase (p38 p38 MAPK _amp_#91 6 _amp_#93
6871MAPK1mitogen-activated protein kinase 1MAPK2.0excitotoxicity by inhibiting the p38 mitogen-activated protein kinase (p38 p38 MAPK _amp_#91 6 _amp_#93
1499CASP1caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase)caspase 11.0first minocycline inhibits microglial activation caspase 1 and inducible nitric oxide synthetase inos up regulation and decreases infarct size after experimental ischemia in rats _amp_#91; 3 4 _amp_#93;.
1499CASP1caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase)caspase 11.0second minocycline inhibits caspase 1 and caspase 3 expression decreases inos activity and delays mortality in a transgenic mouse model of huntington_amp_#39;s disease _amp_#91; 5 _amp_#93;.
1504CASP3caspase 3, apoptosis-related cysteine peptidasecaspase 31.0second minocycline inhibits caspase 1 and caspase 3 expression decreases inos activity and delays mortality in a transgenic mouse model of huntington_amp_#39;s disease _amp_#91; 5 _amp_#93;.
11179SOD1superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult))superoxide dismutase 11.0familial als accounts for 10_amp_#37; of all cases and mutations of the superoxide dismutase 1 sod1 gene have been identified in about 20_amp_#37; of the familial cases.
1499CASP1caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase)caspase 11.0in these in vivo models minocycline prevented completely the ischemia induced activation of microglia as well as the concomitant induction of caspase 1 and inos.
6876MAPK14mitogen-activated protein kinase 14p38 mitogen activated protein kinase1.0however in vitro evidence obtained from a mixed spinal culture model showed that minocycline inhibited the activation and proliferation of microglia induced by excitotoxicity by inhibiting the p38 mitogen activated protein kinase p38 mapk _amp_#91; 6 _amp_#93;.
6193JAK3Janus kinase 3 (a protein tyrosine kinase, leukocyte)janus kinase 31.0a specific inhibitor of janus kinase 3 had the largest effect and increased survival by _amp_#62; 2 months _amp_#91; 18 _amp_#93;.